Analysis of germline variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in familial and sporadic renal cell carcinoma

PLoS ONE

Volumn 4, Issue 6, 2009, Pages

  Ricketts, Christopher ^a   Zeegers, Maurice P ^b,e   Lubinski, Jan ^c   Maher, Eamonn R ^a,d  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c POMERANIAN MEDICAL UNIVERSITY   (Poland)

^d BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

^e MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; INTERSTITIAL COLLAGENASE; SOMATOMEDIN BINDING PROTEIN 3; STROMELYSIN; UVOMORULIN; VASCULOTROPIN; VON HIPPEL LINDAU PROTEIN; AURKA PROTEIN, HUMAN; CADHERIN; CDH1 PROTEIN, HUMAN; IGFBP3 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; SOMATOMEDIN BINDING PROTEIN; VASCULOTROPIN A; VHL PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CANCER RISK; CONTROLLED STUDY; FAMILIAL CANCER; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GERM LINE; HAPLOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; PATHOGENESIS; PENETRANCE; PHENOTYPE; VON HIPPEL LINDAU DISEASE; GENE EXPRESSION REGULATION; GENETICS; KIDNEY TUMOR; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CADHERINS; CARCINOMA, RENAL CELL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; KIDNEY NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; PROTEIN-SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 67650293269     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0006037     Document Type: Article

References (50)

1. Latif F, Tory K, Gnarra J, Yao M, Duh FM, et al. (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260(5112): 1317-20.
2. Foster K, Prowse A, van den Berg A, Fleming S, Hulsbeek MM, et al. (1994) Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 3(12): 2169-73.
3. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, et al. (1994) Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7(1): 85-90.
4. Banks RE, Tirukonda P, Taylor C, Hornigold N, Astuti D, Cohen D, et al. (2006) Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 66(4): 2000-11.
5. Kaelin WG Jr, Maher ER (1998) The VHL tumour-suppressor gene paradigm. Trends Genet 14(10): 423-6.
6. Pavlovich CP, Schmidt LS (2004) Searching for the hereditary causes of renal-cell carcinoma. Nat Rev Cancer 4(5): 381-93.
7. Ricketts C, Woodward ER, Killick P, Morris MR, Astuti D, et al. (2008) Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst 100(17): 1260-2.
8. Teh BT, Giraud S, Sari NF, Hii SI, Bergerat JP, Larsson C, et al. (1997) Familial non-VHL non-papillary clear-cell renal cancer. Lancet 349(9055): 848-9.
9. Woodward ER, Clifford SC, Astuti D, Affara NA, Maher ER (2000) Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes. J Med Genet 37: 348-53.
10. Webster AR, Richards FM, MacRonald FE, Moore AT, Maher ER (1998) An analysis of phenotypic variation in the familial cancer syndrome von Hippel-Lindau disease: evidence for modifier effects. Am J Hum Genet 63(4): 1025-35.
11. Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, et al. (2002) Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res 62(13): 3803-11.
12. Foster RE, Abdulrahman M, Morris MR, Prigmore E, Gribble S, Ng B, et al. (2007) Characterization of a 3;6 translocation associated with renal cell carcinoma. Genes Chromosomes Cancer 46(4): 311-7.
13. Hammerschmied CG, Stoehr R, Walter B, Wieland WF, Hartmann A, Blaszyk H, et al. (2007) Role of the STK15 Phe31Ile polymorphism in renal cell carcinoma. Oncol Rep 17(1): 3-7.
14. Ollerenshaw M, Page T, Hammonds J, Demaine A (2004) Polymorphisms in the hypoxia inducible factor-1alpha gene (HIF1A) are associated with the renal cell carcinoma phenotype. Cancer Genet Cytogenet 153(2): 122-6.
15. Hirata H, Okayama N, Naito K, Inoue R, Yoshihiro S, Matsuyama H, et al. (2004) Association of a haplotype of matrix metalloproteinase (MMP)-1 and MMP-3 polymorphisms with renal cell carcinoma. Carcinogenesis 25(12): 2379-84.
16. Li LC, Chui RM, Sasaki M, Nakajima K, Perinchery G, Au HC, et al. (2000) A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. Cancer Res (4): 873-6.
17. Deal C, Ma J, Wilkin F, Paquette J, Rozen F, Ge B, et al. (2001) Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators. J Clin Endocrinol Metab 86(3): 1274-80.
18. Heighway J, Bowers NL, Smith S, Betticher DC, Koref MF (2005) The use of allelic expression differences to ascertain functional polymorphisms acting in cis: analysis of MMP1 transcripts in normal lung tissue. Ann Hum Genet 69(Pt 1): 127-33.
19. Prior SJ, Hagberg JM, Paton CM, Douglass LW, Brown MD, McLenithan JC, et al. (2006) DNA sequence variation in the promoter region of the VEGF gene impacts VEGF gene expression and maximal oxygen consumption. Am J Physiol Heart Circ Physiol 290(5): H1848-55.
20. Ong KR, Woodward ER, Killick P, Lim C, Macdonald F, Maher ER (2007) Genotype-phenotype correlations in von Hippel-Lindau disease. Hum Mutat 28(2): 143-9.
21. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N (2004) Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 96(6): 434-42.
22. Rutter JL, Mitchell TI, Butticè G, Meyers J, Gusella JF, Ozelius LJ, et al. (1998) A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 58: 5321-5325.
23. Hirata H, Naito K, Yoshihiro S, Matsuyama H, Suehiro Y, Hinoda Y (2003) A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter is associated with conventional renal cell carcinoma. Int J Cancer 106(3): 372-4.
24. Zhu Y, Spitz MR, Lei L, Mills GB, Wu X (2001) A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res 61: 7825-7829.
25. Kanamori Y, Matsushima M, Minaguchi T, Kobayashi K, Sagae S, Kudo R, et al. (1999) Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region. Cancer Res 59: 4225-4227.
26. Ghilardi G, Biondi ML, Mangoni J, Leviti S, DeMonti M, Guagnellini E, et al. (2001) Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness. Clin Cancer Res 7: 2344-2346.
27. Ewart-Toland A, Briassouli P, de Koning JP, Mao JH, Yuan J, Chan F, et al. (2003) Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet 34(4): 403-12.
28. Dicioccio RA, Song H, Waterfall C, Kimura MT, Nagase H, McGuire V, et al. (2004) STK15 polymorphisms and association with risk of invasive ovarian cancer. Cancer Epidemiol Biomarkers Prev 13(10): 1589-94.
29. Ewart-Toland A, Dai Q, Gao YT, Nagase H, Dunlop MG, Farrington SM, et al. (2005) Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis 26(8): 1368-73.
30. Kimura MT, Mori T, Conroy J, Nowak NJ, Satomi S, Tamai K, et al. (2005) Two functional coding single nucleotide polymorphisms in STK15 (Aurora-A) coordinately increase esophageal cancer risk. Cancer Res 65(9): 3548-54.
31. Wang W, Spitz MR, Yang H, Lu C, Stewart DJ, Wu X (2007) Genetic variants in cell cycle control pathway confer susceptibility to lung cancer. Clin Cancer Res 13(19): 5974-81.
32. Niu T, Qin ZS, Xu X, Liu JS (2002) Bayesian haplotype inference for multiple linked single-nucleotide polymorphisms. Am J Hum Genet 70: 157-69.
33. Huber PJ (1967) "The Behavior of Maximum Likelihood Estimates under Nonstandard Conditions." Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability 1: 221-33.
34. StataCorp (2005) Statistical Software: Release 9.0. College Station, TX: Stata Corporation.
35. Basset P, Okada A, Chenard MP, Kannan R, Stoll I, Anglard P, et al. (1997) Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. Matrix Biol 15: 535-541.
36. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000) Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18: 1135-1149.
37. Stetler-Stevenson WG (1999) Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 103: 1237-1241.
38. Rigel DS, Friedman RJ, Kopf AW, Silverman MK (1991) Factors influencing survival in melanoma. Dermatol Clin 9: 631-642.
39. López-Otín C, Matrisian LM (2007) Emerging roles of proteases in tumour suppression. Nat Rev Cancer 7(10): 800-8.
40. Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE (1996) Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 2: 461-462.
41. Murray GI, Duncan ME, O'Neil P, McKay JA, Melvin WT, Fothergill JE (1998) Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 185: 256-261.
42. Ito T, Ito M, Shiozawa J, Naito S, Kanematsu T, Sekine I (1999) Expression of the MMP-1 in human pancreatic carcinoma: relationship with prognostic factor. Mod Pathol 12: 669-674.
43. Zhang J, Jin X, Fang S, Li Y, Wang R, Guo W, et al. (2004) The functional SNP in the matrix metalloproteinase-3 promoter modifies susceptibility and lymphatic metastasis in esophageal squamous cell carcinoma but not in gastric cardiac adenocarcinoma. Carcinogenesis 25: 2519-24.
44. Zinzindohoué F, Blons H, Hans S, Loriot MA, Houllier AM, Brasnu D, et al. (2004) Single nucleotide polymorphisms in MMP1 and MMP3 gene promoters as risk factor in head and neck squamous cell carcinoma. Anticancer Res 24: 2021-6.
45. Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Köppel H, Leithner A, et al. (2004) The 5A/6A polymorphism of the matrix metalloproteinase 3 gene promoter and breast cancer. Clin Cancer Res 10(10): 3518-20.
46. Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, et al. (1998) Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 20(2): 189-93.
47. Hung RJ, Brennan P, Canzian F, Szeszenia-Dabrowska N, Zaridze D, et al. (2005) Large-scale investigation of base excision repair genetic polymorphisms and lung cancer risk in a multicenter study. J Natl Cancer Inst 97(8): 567-76.
48. Koochekpour S, Jeffers M, Wang P, Gong C, Taylor G, Roessler L, et al. (1999) The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol 19: 5902-5912.
49. Katayama H, Sasai K, Kawai H, Yuan ZM, Bondaruk J, Suzuki F, et al. (2004) Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 36: 55-62.
50. Roe JS, Kim H, Lee SM, Kim ST, Cho EJ, Youn HD (2006) p53 stabilization and transactivation by a von Hippel-Lindau protein. Mol Cell 22(3): 395-405.